

## Corrigendum: Table and Text Correction

# Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians

Ahmed Iqbal<sup>1,2,3,\*</sup>, Peter Novodvorsky<sup>1,2,\*</sup>, Simon R. Heller<sup>1,2</sup>

<sup>1</sup>Department of Oncology and Metabolism, University of Sheffield, Sheffield,

<sup>2</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,

<sup>3</sup>Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK

Diabetes Metab J 2018;42:3-18. <https://doi.org/10.4093/dmj.2018.42.1.3>

We have three errors in 'Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians,' these are as follows:

In Table 1, the manufacturer of insulin degludec (Tresiba) was wrongly listed as Sanofi. This should be NovoNordisk.

In the subsection 'INSULIN PREPARATIONS AND ADMINISTRATION,' on page 6, insulin degludec (Tresiba) was mentioned, but without manufacturer, this should be NovoNordisk.

In the subsection 'USE OF METFORMIN IN T1DM,' page 7, the original text 'reduction of progression of caroT-1DM artery intima-media thickness,' should be corrected to 'reduction of progression of carotid artery intima-media thickness.'

We apologize for any inconvenience that this may have caused.